QIAGEN N.V. (QGEN) is well-poised to grow in the coming quarter, driven by its strategic alliances with researchers and pharma companies. The company's expansive next-generation sequencing (NSG) portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to currency fluctuations, which can adversely affect its financial results. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #3 (Hold) stock has risen 6% compared with 4% growth ...

Venlo, the Netherlands, Sept. 26, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE-marking under the European Union's new In-Vitro Diagnostic Medical Devices Regulation (IVDR). This certification includes the widely-used QIAstat-Dx Analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and respiratory illnesses. The achievement underscores QIAGEN's commitment to meeti ...

Core Viewpoint - QIAGEN N.V. and Becton, Dickinson and Company have launched the PAXgene Urine Liquid Biopsy Set, which aims to enhance the analysis of cell-free DNA from urine, addressing a significant market need for reliable urine collection and stabilization solutions [1][7]. Company Developments - The PAXgene Urine Liquid Biopsy Set features a verified, standardized, and complete preanalytical workflow for urine collection, stabilization, and cfDNA isolation, making it compatible with various molecular testing technologies [2][6]. - Following the launch, QIAGEN's shares experienced a decline of 1.7%, closing at $44.11, although the company is expected to benefit from synergies within its Sample Technologies product portfolio [3]. - QIAGEN's market capitalization stands at $10.15 billion, with a recent earnings surprise of 5.77% and a trailing four-quarter average earnings surprise of 2.64% [4]. Product Significance - The PAXgene set is designed to facilitate urine liquid biopsy, which has the potential to aid in detecting minimal residual disease, monitoring treatment responses, and identifying therapeutic targets, thus complementing blood plasma analysis [7]. - This product will complement QIAGEN's existing liquid biopsy solutions, covering a wide range of analytes and molecular detection technologies, thereby enhancing research and clinical applications [8]. Industry Prospects - The global cfDNA testing market was valued at $9.58 billion in 2023 and is projected to grow to $48.03 billion by 2030, with a compound annual growth rate of 25.90%, driven by increasing healthcare expenditure and awareness [10]. - Over the past year, QIAGEN's shares have increased by 8.4%, contrasting with a 0.4% decline in the industry [11].

QIAGEN N.V. (QGEN) recently announced that Bode Technology will be the exclusive global commercial partner for its GEDmatch PRO genealogy database. QIAGEN's subsidiary Verogen inked the deal with Bode. The company has been providing GEDmatch PRO to customers since the acquisition of its subsidiary, Verogen, in early 2023. The latest partnership is aimed at accelerating the use of QIAGEN's next-generation sequencing (NGS) products in human identification (HID) and forensic investigations. QGEN's Likely Stock ...

Venlo, the Netherlands, and Germantown, Maryland, Sept. 23, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Bode Technology, the largest private U.S. forensics laboratory company with a growing presence in other regions, would become the exclusive global commercial partner for the GEDmatch PRO genealogy database, which is used to assist police and forensic teams with investigative comparisons of genetic data. The multi-year agreement between QIAGEN's sub ...

Core Insights - QIAGEN N.V. has launched 100 new assays for its digital polymerase chain reaction (dPCR) platform, QIAcuity, aimed at studying cancer, genetic disorders, infectious diseases, and environmental monitoring [1][3] - The company has exceeded its 2024 target by launching over 130 new assays year to date, contributing to a total of more than 2,300 validated assays [5] - QIAGEN's market capitalization stands at $10.15 billion, with a recent earnings surprise of 5.77% in the last reported quarter [2] Product Development - The newly launched assays include dPCR LNA Mutation, dPCR CNV Probe Assays, and dPCR Microbial DNA Detection Assays, targeting cancer mutations, copy number variations, and critical pathogens [3][4] - QIAGEN plans to expand its dPCR portfolio into clinical testing with an in-vitro diagnostic version of QIAcuity expected in the second half of 2024 [6] Strategic Collaborations - QIAGEN has entered a collaboration with Eli Lilly to develop a QIAstat-Dx in-vitro diagnostic panel for detecting apolipoprotein E (APOE) genotypes [7] - The company has also expanded its Master Collaboration Agreement with AstraZeneca to develop companion diagnostics for chronic diseases [8] Market Outlook - The global digital PCR market is projected to grow from $7.12 billion in 2024 to $17.33 billion by 2034, with a CAGR of 9.3% [9][10] - Increasing demand for accurate nucleic acid testing in clinical diagnostics and advancements in genomics are key factors driving market growth [10] Financial Performance - QIAGEN's shares have increased by 10.4% over the past year, outperforming the industry growth of 0.3% [11]

Core Insights - QIAGEN has launched 100 new assays for its QIAcuity digital PCR platform, targeting applications in cancer research, genetic disorders, infectious disease surveillance, and environmental monitoring [1][2][3] - The company has exceeded its 2024 goal by launching over 130 new assays this year, contributing to a total of more than 2,300 validated assays [2] Product Development - The new assays include dPCR LNA Mutation and dPCR CNV Probe Assays, focusing on cancer-related mutations and copy number variations in genes associated with various cancers [3][4] - dPCR Microbial DNA Detection Assays are designed to identify pathogens linked to infectious diseases and antibiotic resistance, as well as animal and plant diseases [4] Market Adoption - QIAcuity digital PCR has seen strong adoption, with over 2,000 placements by the end of 2023 and citations in over 450 publications, serving key customers in pharmaceuticals, academia, and diagnostics [5] Technological Advancements - The QIAcuity platform utilizes nanoplates for sample partitioning, allowing simultaneous reading of reactions, which reduces processing time from six hours to two [6] - The platform is available in one-, four-, and eight-plate versions, catering to various laboratory sizes and throughput needs [6] Future Plans - An in-vitro diagnostic version of QIAcuity is set to launch in fall 2024, aimed at clinical applications such as diagnosing infectious diseases and monitoring cancer [7] - QIAGEN is collaborating with pharmaceutical companies to develop companion diagnostics using the QIAcuity platform [7]

QIAGEN's (QGEN) business is expected to get a boost from its growing molecular diagnostic market, expanded test menu and growth-driving strategic collaborations. Yet, a challenging macro environment and an intensely competitive market may dent its results of operations. The stock carries a Zacks Rank #3 (Hold) currently. Factors Driving Growth for QGEN Stock QIAGEN offers one of the broadest portfolios of molecular technologies for healthcare. Its range of assays for diseases and biomarkers speeds up and si ...

QIAGEN N.V. (QGEN) announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, a leading vaccines and diagnostics supplier to the Brazilian Ministry of Health. Initiated in 2009, the expanded collaboration allows Bio-Manguinhos to launch an advanced PCR (Polymerase Chain Reaction)-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus, a capability previously unavailable in Brazil's blood donation program. The recent development will also support ep ...

Venlo, the Netherlands, Rio de Janeiro, Brazil, Sept. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its strategic partnership with BioManguinhos/Fiocruz, the leading provider of vaccines and diagnostics to the Brazilian Ministry of Health. The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus. With the expansion of this collaboration, Bio-Manguinho ...